Last updated: 2026-11-15 14:08:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Medtronic plc (MDT) operates in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector and is listed on NYSE. The stock is currently priced at $102.84, with a market capitalization of $131.57B and a P/E ratio of 25.15. Over the past 52 weeks, its price has ranged from $73.31 to $106.33. This page covers its latest market performance, valuation, price trends and company information.
$131.57B | |
$102.10 | |
$103.34 | |
$100.46 | |
$100.99 | |
4.14M | |
16.70M | |
25.15 | |
$106.33 | |
$73.31 | |
2.77% | |
04-24 |
Medtronic plc (MDT) last closed at $102.84 as of 2026-11-14 01:01:00, up 1.85% ($1.87) from the previous close of $100.99.
During the latest regular trading session, MDT traded between $100.46 and $103.34, with a volume of 4.14M shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Medtronic plc (MDT) moved from $104.84 to $102.84, representing a decline of 1.90% ($2.00).
The stock traded between $100.02 and $106.20 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 6.52 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 89.4%
MDT is currently trading at $102.84, placing it 89.4% of the way from its 52-week low of $73.31 to its 52-week high of $106.33. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, surgical robots, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
| Industry | ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS |
| Employees | 95,000 |
| CEO | Geoffrey Straub Martha |
| Founded | 1949 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for Medtronic plc.
Dividend | |
|---|---|
| Ex-Dividend Date | Sep 25, 2026 |
| Payment Date | Oct 16, 2026 |
| Dividend Per Share | $0.72 |
Latest news related to Medtronic plc and MDT stock.
The article recommends five dividend stocks suitable for long-term buy-and-hold investors: Johnson & Johnson, Medtronic, Procter & Gamble, Federal Realty Investment Trust, and Realty Income. All five companies have strong dividend track records with at least 32 years of consecutive annual increases, combined with well-run underlying businesses that generate reliable income streams.
MacroGenics reported a quarterly loss of $0.34 per share, significantly worse than the consensus estimate of $0.10 loss, representing a -240% earnings surprise. Revenue also missed expectations at $18.67 million versus consensus, down 74% year-over-year. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions ahead.
The global Transcatheter Aortic Valve Replacement (TAVR) market is projected to grow from US$ 8.41 billion in 2025 to US$ 30.01 billion by 2035, driven by increasing prevalence of aortic stenosis, aging populations, and rising adoption of minimally invasive cardiac procedures. Technological advancements in valve platforms and delivery systems are creating growth opportunities, with Asia Pacific emerging as the fastest-growing region.
Abbott (ABT) announced FDA and CE Mark approvals for its UltiSynq defibrillation lead, which delivers both pacing and defibrillation therapy. The ASCEND CSP IDE trial demonstrated a 98.5% successful implantation rate, 97.5% complication-free rate, and 100% successful defibrillation in 120 tested patients. The device received FDA breakthrough designation. Competitors Medtronic and Boston Scientific also reported positive clinical results for their respective cardiac devices.
Eligible investors can buy real shares of Medtronic plc (MDT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Browse other US stocks in the same sector as Medtronic plc
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to MDT, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between MDT shares and USD.
MDT Shares to USD
1.00 MDT shares = 102.843 USD
Calculations are estimates based on the latest available price and are for reference only.
